Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Clinical Drug Investigation · 2025-05 · 45 (5) · 235-245
DOI: 10.1007/s40261-025-01436-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Drug Investigation, online erschienen am 04.04.2025. Verfasst von Ana Carolina Putini Vieira und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicine, University of Santo Amaro, São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Chronic Urticaria, Antibodies, Monoclonal, Humanized, Anti-Allergic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: This meta-analysis aims to evaluate ligelizumab's efficacy and safety for chronic spontaneous urticaria (CSU) treatment by analyzing recent clinical trials and comparing it with placebo and omalizumab. METHODS: PubMed, Embase, and Cochrane were searched up to October 2024. Eligible studies were randomized controlled trials (RCTs) comparing ligelizumab with placebo or omalizumab, reporting relevant outcomes. Nonrandomized studies, or those without control groups, were excluded. Risk of bias was assessed using the Cochrane RoB-2 tool, and the Grading of Recommendation, Assessment, Development, and Evaluations approach rated evidence certainty. Statistical analysis used R software (v.4.4.2), assessing heterogeneity by Cochran Q and I2 statistics. RESULTS: Four RCTs with 2488 patients were included. Ligelizumab ( 72 mg dose showed greater improvements in ISS7 (RR 5.12; 95% CI 2.72-9.64; PI 1.14-22.96; P 72 mg), omalizumab had fewer injection site reactions (RR 3.04; 95% CI 1.95-4.73; PI 0.17-53.81; P 72 mg, improvements in overall urticaria activity were seen, but ISS7 and UAS7 were classified as low quality of evidence. DISCUSSION: Ligelizumab significantly improves CSU symptoms compared with placebo, reducing disease severity, itching, and hives, with similar safety to omalizumab. Ligelizumab's higher affinity for immunoglobulin E (IgE) may provide better symptom control. Limitations include a small number of studies, short follow-up periods, and patient variability. PROTOCOL REGISTRATION: International Prospective Register of Systematic Reviews (PROSPERO), CRD42024593072.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medicine, University of Santo Amaro, São Paulo, São Paulo, Brazil.
- Division of Medicine, Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil.
- Division of Medicine, Centro Universitário Maurício de Nassau de Barreiras, Barreiras, Bahia, Brazil.
- Division of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
- Division of Medicine, City University of São Paulo, São Paulo, São Paulo, Brazil.
- Division of Medicine, Catholic University of Brasília, Brasília, Distrito Federal, Brazil.
Zitieren
APA
Vieira, A. C. P., Ventura de Santana de Jesus, A. C., Cappellaro, A. P., Barbosa, L. M., de Farias Santos, A. C. F., de Medeiros, C. M. D., Pereira, M., Lopes, G. G., & Zamora, F. V. (2025). Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Drug Investigation, 45(5), 235-245. https://doi.org/10.1007/s40261-025-01436-9
Vancouver
Vieira ACP, Ventura de Santana de Jesus AC, Cappellaro AP, Barbosa LM, de Farias Santos ACF, de Medeiros CMD, et al. Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Drug Investigation. 2025;45(5):235-245. doi:10.1007/s40261-025-01436-9
BibTeX
@article{Vieira2025,
author = {Vieira, Ana Carolina Putini and Ventura de Santana de Jesus, Ana Carolina and Cappellaro, Anelise Poluboiarinov and Barbosa, Lucas M and de Farias Santos, Ana Clara Felix and de Medeiros, Carolina Mira Dilly and Pereira, Mable and Lopes, Gabriel Gomes and Zamora, Fernanda Valeriano},
title = {Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-analysis of Randomized Controlled Trials},
journal = {Clinical Drug Investigation},
year = {2025},
volume = {45},
number = {5},
pages = {235--245},
doi = {10.1007/s40261-025-01436-9}
}
EUVIMED